3. Roivant Sciences Ltd. (NASDAQ:ROIV)
Number of Hedge Fund Holders In Q2 2024: 62
Share Price: $11.57
Roivant Sciences Ltd. (NASDAQ:ROIV) is a biotechnology company that works with patents and develops medicines for commercial sales. This makes treatments under development and potential litigation win the two keys to its hypothesis, and provides it with a wide portfolio courtesy of its ownership stakes in 11 companies. On the former front, Roivant Sciences Ltd. (NASDAQ:ROIV) currently has three treatments under development through its Immunovant subsidiary. These are IMVT-1401 which seeks to help patients with immune system diseases, mosliciguat for heart problems stemming from lung disease, and a treatment for psoriasis called brepocitinib. The firm also entered into a $1.2 billion deal for its Dermavant business recently which offered it $175 million in upfront payments which will help Roivant Sciences Ltd. (NASDAQ:ROIV) manage operating and research expenses as it brings its drugs to the market after trials. The company could see additional catalysts if its drugs like IMVT-1402 are able to help patients with other diseases such as anemia and polyneuropathy. The performance of its treatments in trials and associated data could influence share price movements. Another catalyst could be a patent win against Moderna and Pfizer for raw materials used to make COVID vaccines.
Roivant Sciences Ltd. (NASDAQ:ROIV)’s management shared details for two of its under development drugs during the Q1 2025 earnings call:
“We have continued clinical development beyond that in our pipeline including in brepocitinib where we’ll be beginning our Phase 3 program in NIU shortly where we have data coming in namilumab and sarcoidosis and so on. We’re very much looking forward to. We’ll talk a little bit about VTAMA today, but the story for VTAMA for this year is really the expansion of the label with AD and some acceleration of psoriasis, certainly volumes and revenues are over time. And then we continue to be hard at work expanding our pipeline looking at mid-late-stage programs. I know there’s a lot of focus on that activity. We will be unveiling our much discussed so far undisclosed program just next month, so hold on for a few more weeks there. And then, continuing to work on prioritizing capital allocation we thinking aggressively around the use of capital to continue to buy back shares and so on.
We are super proud on slide 6 of the pipeline as it currently stands. And one of the things that — I’m sure sometimes you get all these questions about IMVT, but every time I look at our pipeline, we still have one of the best I&I pipelines without IMVT, so excited about the breadth of opportunities there, in particular excited about the next, call it, 18 months both in the [indiscernible], we’ll talk a lot more about today and then brepocitinib where we have pivotal data coming shortly. So, the main updates for the quarter starting on slide 8. One is on brepocitinib, which is that we’ve now completed enrollment in our Phase 3 study in dermatomyositis. It’s 241 subjects across 90 sites. It is the largest interventional DM study ever conducted.
And we can now say with confidence we expect top line data in the second half of next year that study completed enrollment a few weeks back.”
